On September 27, GeLongHui reported that Jointown Pharmaceutical (300966.SZ) announced that the company recently received a notice of the share reduction plan issued by the controlling shareholder and actual controller's concerted action person, Danjiangkou City Joint Innovation Investment Partnership Enterprise (Limited Partnership) (hereinafter referred to as 'Dan Innovation Venture Capital'), and Zhang Xin. Dan Innovation Venture Capital holds 5,501,200 shares of the company, accounting for 4.77% of the total share capital of the company; Zhang Xin holds 1,490,900 shares of the company, accounting for 1.22% of the total share capital. Dan Innovation Venture Capital and Zhang Xin plan to reduce their shareholding by no more than 3,458,367 shares (i.e. not more than 3% of the current total share capital of the company) through centralized bidding or block trading. If reducing through centralized bidding, it is planned to be carried out within 3 months after 15 trading days from the date of this announcement, with the total number of shares reduced not exceeding 1% of the total shares of the company within any consecutive 90 days; if reducing through block trading, it is planned to be carried out within 3 months after 15 trading days from the date of this announcement, with the total number of shares reduced not exceeding 2% of the total shares of the company within any consecutive 90 days.